Loading…
Loading…
IQV does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for IQV and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for IQV and 80,000+ other tickers.
See exactly how IQV's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IQV and 80,000+ other tickers.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions…
IQV is poised for y/y revenue and earnings growth in Q3, driven by stronger clinical research demand, solid bookings, AI adoption and operational efficiencies.
IQVIA Holdings (IQV) is rated Buy, supported by strong Q2 results and a robust R&D bookings recovery. Q2 revenue grew 8.7% to $4.37B, with adjusted EPS up 12.1% and R&D net new bookings surging 19% to $3.15B. Commercial Solutions delivered 8.6% revenue growth, with AI adoption and data assets driving margin expansion and cross-selling opportunities.
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Maia Wealth LLC trimmed its position in shares of IQVIA Holdings Inc. (NYSE: IQV) by 44.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,678 shares of the medical research company's stock after selling 2,886 shares during the quarter. Maia Wealth
First Citizens Bank and Trust Co. acquired a new position in shares of IQVIA Holdings Inc. (NYSE: IQV) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 5,160 shares of the medical research company's stock, valued at approximately $1,387,000. Several other institutional investors